Scalable, single-molecule and single-cell chromatin accessibility profiling in primary immune cells

Active Grant Awarded

Award ID
R44AI197362
Recipient
Awarding agency
Obligated
$999,268

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 9% complete
Place of performance
Durham, NC 27709, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Epicypher, Inc. $999,268 under Grant R44AI197362, Allergy and Infectious Diseases Research (CFDA 93.855), on August 21, 2026. The award funds DAF-SEQ, an amplification-compatible multiomic long-read sequencing assay that resolves haplotype-phased sequence and chromatin accessibility of single molecules. Epicypher is developing the assay with Dr. Andrew Stergachis of the University of Washington. Nuclei are treated with a non-specific deaminase that marks accessible cytidine residues, stenciling chromatin accessibility onto individual DNA fibers during amplification before long-read sequencing. The stated aim is single-cell resolution, where the source notes that existing direct-sequencing approaches require large cell numbers and sequencing depth. The period of performance runs from August 21, 2026 through ultimate completion on July 31, 2029. Work is performed in Durham, North Carolina 27709. The full $999,268 is obligated. The program supports public and private nonprofit institutions and individuals in establishing, expanding, and improving biomedical research and research training in infectious diseases and related areas, and in studying infectious, immunologic, and allergic diseases.

Description

Abstract
Chromatin structure dictates which genes and regulatory elements are active and which genomic elements are silenced through accessibility. Profiling accessible regulatory elements and the proteins that bind them is critical for understanding the functions and developmental fate of immune cells. Popular assays to study chromatin accessibility use short-read sequencing (SRS). Long-read sequencing (LRS) platforms can directly sequence DNA, generating reads >10KB in length and preserving relationships between sequence and epigenomic features of single molecules. These long reads can be used to resolve heterogeneity through analysis of cell specific signatures in mixed cell populations. LRS-based accessibility assays provide an unprecedented opportunity to decipher the chromatin structure of circulating immune cells or cells in complex tissues like lymph nodes. Recently, novel LRS-compatible chromatin accessibility assays have been developed. However, these approaches require direct sequencing of the modified DNA, which requires large cell numbers and sequencing depth, limiting application to rare cell populations and single cells (SCS). An amplification- compatible LRS chromatin stenciling method would enable analysis of haplotype-specific chromatin structure at SC resolution with coverage far exceeding all existing SC epigenomic technologies. Here, epicypher is collaborating with DR. Andrew stergachis (university of washington) to develop DAF-SEQ, an amplification-compatible multiomic LRS profiling assay to resolve haplotype phased sequence and chromatin accessibility of single molecules. In this approach, nuclei are treated with a non-specific deaminase to deaminate accessible cytidine residues, thereby 'stenciling' the chromatin accessibility onto individual fibers during DNA amplification, followed by LRS. With DAF-SEQ, we observe single-molecule protein occupancy within broader accessible chromatin regions. Further, because the accessibility information is retained during amplification, DAF-SEQ is ideal for samples with low cell numbers, even single cells. In phase I, we developed a targeted DAF-SEQ workflow that provides a ~200,000-fold enrichment relative to leading genome-wide LRS- based methods. We leveraged this enrichment to identify strand-specific protein footprinting at a well- characterized promoter. Finally, we developed a single cell DAF-SEQ workflow, generating the first whole genome accessibility profile from a single cell, increasing genome coverage 7,000X VS. Current scatac-SEQ assays using SRS. In phase II, we will benchmark our non-specific deaminase against an additional deaminase and develop robust DAF-SEQ protocols using multiple immune cell types (aim 1). Following, we will optimize enrichment of immune-specific genomic loci and validate DAF-SEQ analysis at these loci to enable deconvolution of mixed cell populations (aim 2). Finally, we will prepare for commercialization by assembling DAF-SEQ beta kits, launching a web-based bioinformatics portal, and demonstrating the application of DAF-SEQ to profile full-length haplotype- specific chromatin accessibility and protein occupancy from single cells (aim 3).

Quick answers

Who received award R44AI197362?

R44AI197362 was awarded to Epicypher, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 21, 2026.

How much is award R44AI197362 worth?

$999,268 has been obligated on R44AI197362.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award